

Spinomix Press Release

Lausanne, March 12 2008

Spinomix announced today that they had signed a **collaborative development agreement** with a US based company focused on molecular diagnostics. While specific terms were not disclosed, Spinomix will receive a cash payment and potential for subsequent milestone payments. The objective of the project is to explore if and how Spinomix's proprietary MagPhase™ technology - an innovative method of minute manipulation of coated magnetic nano-particles in a micro-fluidic lab-on-a-chip – can be integrated with the collaborator's proprietary detection technology. The molecular diagnostics market is poised for rapid growth with the recent introduction of new molecular tests such as identification of HPV types and detection of Hospital Acquired Infections. The challenge remains in developing an easy to use 'sample-in, answer-out' system as such instrument that could significantly change the landscape of molecular diagnostics. The parties share the vision that joint development could lead to a dramatic decrease in the cost and complexity and thus further broaden and popularize molecular diagnostics in small and midsize laboratories, benefiting the broader population. As a result, both companies are excited to work together on this development project.

At the same time Spinomix welcomes **Jean-Louis Rufener as an Executive VP Sales & Marketing** starting on April 1 2008. Jean-Louis, a chemical engineer by background, has 37+ yrs of extensive working experience in the diagnostic industry as a Senior Vice President, International Operations, Global Sales and Marketing, Caliper Life Sciences, President & CEO of Scitec Automation Laboratories, President of Tecan, Director of S&M Merz & Dade, Business Manager of Kontron.

Tomas Svoboda, CEO of Spinomix said: "The signature of the agreement with the US based company further confirms the relevance of Spinomix technology for the dynamically growing molecular diagnostic segment. We should know within the next 2-3 quarters whether the joint development efforts would lead to the anticipated results. In positive case closer commercial cooperation is anticipated.

We, at Spinomix are delighted that such a seasoned senior executive joins our young organization and strengthen the competencies and expertise of our team. Jean-Louis should contribute to prepare the roll out of Spinomix products in professional and efficient fashion and in the most appropriate market segments. Further team enlargements are anticipated in the coming months as we go ahead".

Spinomix SA – is an early stage company based in Lausanne, Switzerland which develops innovative technologies for the biomolecular market with the intention to simplify many labor and cost intensive manipulations in molecular diagnostic and sample preparation. The company's patent portfolio and close cooperation with three life science focused universities on Lake Geneva provide an important spring board in this rapidly growing market segment.